tirzepatide side effects constipation Effects: Timeline, Symptoms, Weight Regain & Long-Term Safety Tirzepatide Side Effects: Common &
Description
The Phase 3 ATTAIN-1 trial showed the 36 mg dose achieved 11.2% mean body weight reduction over 72 weeks
In SURMOUNT-5, gastrointestinal adverse events were common in both groups, which is expected for this drug class
Prescribers must: Document a clear clinical rationale
We never use a gray-market source for any medication
However, noticeable weight loss may not begin until individuals reach their maintenance dose
